Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Trevi Therapeutics Inc TRVI

Healthcare Biotechnology
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TRVI)

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer

PR Newswire 11 days ago

Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

PR Newswire November 13, 2025

Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

PR Newswire November 6, 2025

Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

PR Newswire November 4, 2025

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

PR Newswire October 8, 2025

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

PR Newswire September 18, 2025

Trevi Therapeutics to Participate in Upcoming September Conferences

PR Newswire August 28, 2025

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

PR Newswire August 7, 2025

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

PR Newswire July 31, 2025
View More News ››

Opinion & Analysis (NDAQ:TRVI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TRVI)

Healthcare works in a recession

could see this sector rise
Tradinghands - March 10, 2025

Using technical analysis for this one.

This stock is signalling strength to the upside this morning
coolfooldumbguy - March 10, 2025

Trevi Therapeutics, Inc. (TRVI): Advancing Haduvio for Chron

http://beyondspx.com/2024/08/02/trevi-therapeutics-inc-trvi-advancing-haduvio-for-chronic-cough-indications-with-robust-clinical-pipeline...
MikeTester - August 3, 2024
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. together with its subsidiaries, engages in the acquisition, exploration, and development of uranium ...
View More »